Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Candesartan · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Candesartan QD + Heart Failure Therapy | EXPERIMENTAL | (with angiotensin-converting enzyme-inhibitors/beta-blockers) |
| Placebo QD + Heart Failure Therapy | PLACEBO_COMPARATOR | (with angiotensin-converting enzyme-inhibitors/beta-blockers) |
| Name | Type | Description |
|---|---|---|
| Candesartan | DRUG | Candesartan up to 32 mg, tablets, orally, once daily and ongoing angiotensin-converting enzyme inhibitor/beta-blocker therapy for up to 24 weeks. |
| Placebo | DRUG | Candesartan matching-placebo tablets, orally, once daily and ongoing angiotensin-converting enzyme inhibitor/beta-blocker therapy for up to 24 weeks. |
Inclusion Criteria: * Diabetes mellitus type 2 - insulin dependent or orally treated or managed by diet for at least 3 Months. * Normotension or controlled hypertension with sitting Systolic Blood Pressure less than 140 mmHg and/or sitting Diastolic Blood Pressure less than 90 mmHg. * Regular sinus...
Top 20 of 31 competitors